The following information is limited to United Therapeutics sponsored studies. Information is not intended to offer recommendations for any administration, indication, dosage, or other use inconsistent with approved prescribing information.

AMCP Annual Meeting 2018

+

−

Treatment with prostacyclins reduces hospital readmissions among patients with pulmonary arterial hypertension

AMCP Nexus 2018

+

−

The relationship between non-invasive endpoints and long-term outcomes in pulmonary arterial hypertension: six-minute walk, functional class and brain natriuretic peptide

Predicting adherence to oral treprostinil in patients with pulmonary arterial hypertension

Increasing treprostinil dose reduces annual hospitalization rates and consequent costs in patients with pulmonary arterial hypertension

ASCO Annual Meeting 2018

+

−

A Two-Part, Open-Label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan versus Irinotecan for Second-Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer

ATS International Conference 2018

+

−

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction—Design of Study TDE-HF-301

Transition to Oral Treprostinil from Parenteral or Inhaled Treprostinil or as Add-on Therapy in Pediatric Subjects with Pulmonary Arterial Hypertension

Combination therapy reduces hospitalizations in patients with pulmonary arterial hypertension

Electrocardiographic Effects of Esuberaprost (BPS-314d) Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Adult Subjects: A Thorough QT Study

Novel analysis of treprostinil dose-response relationship using weight-normalized dosing

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension Due to Parenchymal Lung Disease (Study RIN-PH-201)

CHEST Annual Meeting 2018

+

−

The Effect of Treprostinil Dose on Time to All Cause and Pulmonary Arterial Hypertension-Related Hospitalizations

Esuberaprost

+

−

Electrocardiographic Effects of Esuberaprost (BPS-314d) Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Adult Subjects: A Thorough QT Study

European Lung Cancer Congress 2018

+

−

88P Feasibility of outpatient dinutuximab (D) and irinotecan (I) for second-line treatment of relapsed or refractory small cell lung cancer (RR SCLC): Part 1 of an open-label, randomized, phase 2/3 study

ISPOR Conference 2018

+

−

Treatment with prostacyclins delays and reduces hospital readmissions among PAH patients

Orenitram® (treprostinil) Extended-Release Tablets

+

−

Treatment with prostacyclins delays and reduces hospital readmissions among PAH patients

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction—Design of Study TDE-HF-301

Transition to Oral Treprostinil from Parenteral or Inhaled Treprostinil or as Add-on Therapy in Pediatric Subjects with Pulmonary Arterial Hypertension

The Effect of Treprostinil Dose on Time to All Cause and Pulmonary Arterial Hypertension-Related Hospitalizations

Predicting adherence to oral treprostinil in patients with pulmonary arterial hypertension

Treatment with prostacyclins reduces hospital readmissions among patients with pulmonary arterial hypertension

The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: a meta-analysis

Combination therapy reduces hospitalizations in patients with pulmonary arterial hypertension

Novel analysis of treprostinil dose-response relationship using weight-normalized dosing

Increasing treprostinil dose reduces annual hospitalization rates and consequent costs in patients with pulmonary arterial hypertension

Pharmacokinetics of oral treprostinil in children with pulmonary arterial hypertension

Dosing characteristics of oral treprostinil in real-world clinical practice

Remodulin® (treprostinil) Injection

+

−

Treatment with prostacyclins delays and reduces hospital readmissions among PAH patients

The Effect of Treprostinil Dose on Time to All Cause and Pulmonary Arterial Hypertension-Related Hospitalizations

Treatment with prostacyclins reduces hospital readmissions among patients with pulmonary arterial hypertension

Combination therapy reduces hospitalizations in patients with pulmonary arterial hypertension

Novel analysis of treprostinil dose-response relationship using weight-normalized dosing

Increasing treprostinil dose reduces annual hospitalization rates and consequent costs in patients with pulmonary arterial hypertension

Stability of treprostinil with diluents and medications

Tyvaso® (treprostinil) Inhalation Solution

+

−

Treatment with prostacyclins delays and reduces hospital readmissions among PAH patients

Treatment with prostacyclins reduces hospital readmissions among patients with pulmonary arterial hypertension

The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: a meta-analysis

Combination therapy reduces hospitalizations in patients with pulmonary arterial hypertension

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension Due to Parenchymal Lung Disease (Study RIN-PH-201)

Unituxin® (dinutuximab) Injection

+

−

88P Feasibility of outpatient dinutuximab (D) and irinotecan (I) for second-line treatment of relapsed or refractory small cell lung cancer (RR SCLC): Part 1 of an open-label, randomized, phase 2/3 study

A Two-Part, Open-Label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan versus Irinotecan for Second-Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer